DHPS and melanoma: Key molecular targets in this process, including ODC1, AMD1, DHPS and c-Myc could serve as effective drug targets addressing specific vulnerabilities in BRAFi resistant melanoma, warranting development of novel breakthrough therapies against therapy resistant melanoma.